Wei Zou

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Medicine, Oncology, Pharmacology +12

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

David F. McDermott, Jeffrey A. Sosman, Mario Sznol et al. · Journal of Clinical Oncology · 2016 · 558 citations

Medicine, Oncology, Pharmacology +17

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2021 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17